Richard Law CFA
Stock Analyst at Goldman Sachs
(3.53)
# 2,265
Out of 4,974 analysts
129
Total ratings
44.9%
Success rate
7.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Law CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OLMA Olema Pharmaceuticals | Reiterated: Buy | $20 → $18 | $9.78 | +84.05% | 11 | Sep 14, 2026 | |
| PTGX Protagonist Therapeutics | Reiterated: Buy | $186 | $143.40 | +29.71% | 8 | Aug 31, 2026 | |
| VRDN Viridian Therapeutics | Reiterated: Buy | $39 → $40 | $21.83 | +83.23% | 11 | Aug 19, 2026 | |
| MLYS Mineralys Therapeutics | Reiterated: Buy | $42 → $40 | $28.91 | +38.36% | 13 | Aug 12, 2026 | |
| BCAX Bicara Therapeutics | Rated: Hold | $18 → $20 | $22.67 | -11.78% | 5 | Aug 11, 2026 | |
| RCUS Arcus Biosciences | Rated: Buy | $34 → $42 | $24.32 | +72.70% | 4 | Aug 10, 2026 | |
| CLDX Celldex Therapeutics | Reiterated: Hold | $34 → $38 | $38.51 | -1.32% | 7 | Aug 7, 2026 | |
| SLN Silence Therapeutics | Reiterated: Sell | $4 | $12.46 | -67.90% | 4 | Jul 27, 2026 | |
| COAG Hemab Therapeutics Holdings | Reiterated: Buy | $36 → $46 | $40.27 | +14.23% | 2 | Jul 13, 2026 | |
| MLTX MoonLake Immunotherapeutics | Reiterated: Sell | $11 → $12 | $12.20 | -1.64% | 8 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $3 | $3.41 | -12.02% | 7 | Mar 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $29 → $33 | $23.51 | +40.37% | 3 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $30 → $33 | $29.95 | n/a | 2 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $36 → $31 | $11.17 | n/a | 6 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $47 | $23.22 | n/a | 4 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $62 → $63 | $51.83 | n/a | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $36 → $37 | $113.15 | n/a | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $76 | $11.36 | n/a | 7 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $11 | $12.99 | n/a | 3 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $61 | $8.26 | n/a | 5 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $15 → $14 | $2.63 | n/a | 3 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $10 | $3.43 | n/a | 2 | Feb 24, 2023 |
Olema Pharmaceuticals
Sep 14, 2026
Reiterated: Buy
Price Target: $20 → $18
Current: $9.78
Upside: +84.05%
Protagonist Therapeutics
Aug 31, 2026
Reiterated: Buy
Price Target: $186
Current: $143.40
Upside: +29.71%
Viridian Therapeutics
Aug 19, 2026
Reiterated: Buy
Price Target: $39 → $40
Current: $21.83
Upside: +83.23%
Mineralys Therapeutics
Aug 12, 2026
Reiterated: Buy
Price Target: $42 → $40
Current: $28.91
Upside: +38.36%
Bicara Therapeutics
Aug 11, 2026
Rated: Hold
Price Target: $18 → $20
Current: $22.67
Upside: -11.78%
Arcus Biosciences
Aug 10, 2026
Rated: Buy
Price Target: $34 → $42
Current: $24.32
Upside: +72.70%
Celldex Therapeutics
Aug 7, 2026
Reiterated: Hold
Price Target: $34 → $38
Current: $38.51
Upside: -1.32%
Silence Therapeutics
Jul 27, 2026
Reiterated: Sell
Price Target: $4
Current: $12.46
Upside: -67.90%
Hemab Therapeutics Holdings
Jul 13, 2026
Reiterated: Buy
Price Target: $36 → $46
Current: $40.27
Upside: +14.23%
MoonLake Immunotherapeutics
May 11, 2026
Reiterated: Sell
Price Target: $11 → $12
Current: $12.20
Upside: -1.64%
Mar 27, 2026
Reiterated: Sell
Price Target: $3
Current: $3.41
Upside: -12.02%
Feb 27, 2026
Reiterated: Hold
Price Target: $29 → $33
Current: $23.51
Upside: +40.37%
Jul 24, 2025
Reiterated: Hold
Price Target: $30 → $33
Current: $29.95
Upside: n/a
Aug 15, 2023
Reiterated: Hold
Price Target: $36 → $31
Current: $11.17
Upside: n/a
Aug 9, 2023
Reiterated: Hold
Price Target: $47
Current: $23.22
Upside: n/a
Aug 8, 2023
Reiterated: Hold
Price Target: $62 → $63
Current: $51.83
Upside: n/a
Aug 4, 2023
Reiterated: Hold
Price Target: $36 → $37
Current: $113.15
Upside: n/a
Jun 13, 2023
Reiterated: Buy
Price Target: $76
Current: $11.36
Upside: n/a
May 12, 2023
Reiterated: Hold
Price Target: $11
Current: $12.99
Upside: n/a
May 5, 2023
Reiterated: Buy
Price Target: $61
Current: $8.26
Upside: n/a
May 5, 2023
Reiterated: Hold
Price Target: $15 → $14
Current: $2.63
Upside: n/a
Feb 24, 2023
Upgraded: Hold
Price Target: $10
Current: $3.43
Upside: n/a